ASX:AVR

Anteris Technologies Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive AVR News and Ratings via Email

Sign-up to receive the latest news and ratings for Anteris Technologies and its competitors with MarketBeat's FREE daily newsletter.


About Anteris Technologies

Anteris Technologies Ltd operates as a structural heart company. The company offers ADAPT technology, which re-engineers xenograft tissue into a pure collagen scaffold; and develops DurAVRTM, a 3D single piece aortic valve for the treatment of aortic stenosis. It also researches and develops regenerative medicine and immunotherapies. The company was formerly known as Admedus Limited and changed its name to Anteris Technologies Ltd in May 2020. Anteris Technologies Ltd was incorporated in 1999 and is based in Toowong, Australia.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank™

Overall MarketRank™

0.33 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Anteris Technologies (ASX:AVR) Frequently Asked Questions

What stocks does MarketBeat like better than Anteris Technologies?

Wall Street analysts have given Anteris Technologies a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Anteris Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Anteris Technologies' key executives?

Anteris Technologies' management team includes the following people:
  • Mr. Wayne G. Paterson, CEO, MD & Exec. Director (Age 54, Pay $1.52M)
  • Mr. Matthew McDonnell, Chief Financial Officer
  • Mr. David St. Denis, Chief Operating Officer
  • Ms. Martha Engel, Gen. Counsel
  • Mr. Stephen Denaro, Independent Non-Exec. Director & Company Sec.
  • Mr. Chris Olig, Bus. Devel. and Portfolio Planning Director
  • Mr. Danny Zanardo, Commercial Director of International
  • Prof. Ian Hector Frazer, Exec.

Who are some of Anteris Technologies' key competitors?

Some companies that are related to Anteris Technologies include 4DMedical (4DX), Adherium (ADR), ADM Tronics Unlimited (ADMT), Allegra Orthopaedics (AMT), Analytica (ALT), AnteoTech (ADO), Asensus Surgical (ASXC), Atomo Diagnostics (AT1), AVITA Medical (AVH), Azure Healthcare Limited (AZV.AX) (AZV), Cannabix Technologies (BLO), CleanSpace (CSX), Cochlear (COH), Cochlear (CHEOY) and Cochlear (CHEOF).
View all of AVR's competitors.

What is Anteris Technologies' stock symbol?

Anteris Technologies trades on the ASX under the ticker symbol "AVR."

How much money does Anteris Technologies make?

Anteris Technologies has a market capitalization of $0.00 and generates $7.08 million in revenue each year.

What is Anteris Technologies' official website?

The official website for Anteris Technologies is www.anteristech.com.

How can I contact Anteris Technologies?

The company can be reached via phone at 61 1300 550 310.


This page was last updated on 7/29/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.